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Nine dicationically substituted bis-benzimidazoles were examined for their in vitro activities against Giardia
lamblia WB (ATCC 30957). The potential mechanisms of action of these compounds were evaluated by
investigating the relationship among in vitro antigiardial activity and the affinity of the molecules for DNA and
their ability to inhibit the activity of giardial topoisomerase II. Each compound demonstrated antigiardial
activity, as measured by assessing the incorporation of [methyl-3H]thymidine by giardial trophozoites exposed
to the test agents. Three compounds exhibited excellent in vitro antigiardial activities, with 50%o inhibitory
concentrations which compared very favorably with those of two currently used drugs, quinacrine HCI and
metronidazole. Putative mechanisms of action for these compounds were suggested by the strong correlation
observed among in vitro antigiardial activity and the affinity of the molecules for natural and synthetic DNA
and their ability to inhibit the relaxation activity of giardial topoisomerase II. A strong correlation between the
DNA binding affinity of these compounds and their inhibition of giardial topoisomerase II activity was also
observed.
Giardia lamblia is a common cause of endemic and
epidemic diarrheal disease throughout the world. Some
individuals harbor asymptomatic infections, while others
may exhibit acute or chronic gastrointestinal disease. Four
agents are presently used to treat giardiasis: the nitroimida-
zoles metronidazole and tinidazole, the nitrofuran furazoli-
done, and quinacrine HCl, an acridine. Many problems are
associated with the currently used chemotherapeutic agents,
including treatment failures, unpleasant side effects, activity
against normal intestinal flora, and possible carcinogenicity.
While treatment of symptomatic individuals is recom-
mended, there is controversy as to whether asymptomatic
cyst passers should be treated, especially in light of the
problems associated with the antigiardial agents presently
available. More-effective and less-toxic agents are therefore
needed for the treatment of giardiasis.
The search for new antigiardial agents has been aided by
improvements in axenic culturing of the organism (13) and
drug susceptibility testing (3, 12). Among the classes of
compounds recently examined for antigiardial activity are
anthelminthic benzimidazoles (1, 8, 14, 15) and derivatives
of the antiprotozoal compound pentamidine (2). Pentamidine
and 38 related dicationically substituted molecules were
examined for in vitro activities against G. lamblia (2). The
50% inhibitory concentration values (IC50s) of the pentami-
dine analogs demonstrating the most potency against G.
lamblia compared favorably with those of the compounds
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which are used at present to treat the infection (2). In
addition, there was a strong correlation between the antigia-
rdial activities of the pentamidine analogs and their affinity
for calf thymus DNA and poly(dA) poly(dT). The ability of
pentamidine to bind to DNA has been proposed as a mech-
anism of action for this and related compounds. Pentamidine
and related molecules have also been identified as potential
inhibitors of the activity of type II topoisomerases (7, 17).
A number of dicationically substituted bis-benzimida-
zoles, originally developed as protease inhibitors and DNA
binding agents, were available in our laboratory for in vitro
antimicrobial susceptibility testing. These compounds have
shown antiarthritic activity in an animal model (11) and have
also demonstrated in vivo activity against Pneumocystis
carinii pneumonia in the rat model of disease (20). Several of
the bis-benzimidazoles also exhibit affinities for DNA stron-
ger than those of the pentamidine derivatives (9). This fact,
coupled with the correlation between the antigiardial activity
and DNA binding affinity of the pentamidine derivatives,
prompted us to expand our studies. The present report
describes the examination of the structure-activity relation-
ships of nine dicationically substituted bis-benzimidazoles
against G. lamblia in vitro, the correlation between their
antigiardial activities and their affinities for natural and
synthetic DNA, and their ability to inhibit the activity of
giardial topoisomerase II.
MATERIALS AND METHODS
Chemotherapeutic agents. The bis-benzimidazoles used in
the present study were synthesized according to previously
described methods (6, 9, 18, 19). The purity of the com-
pounds was determined by high-performance liquid chroma-
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tography, elemental analyses, and nuclear magnetic reso-
nance spectroscopy. Quinacrine-HCl and metronidazole
were purchased from Sigma (St. Louis, Mo.).
Cultivation and isolation of parasites. G. lamblia (WB)
trophozoites (ATCC 30957) were grown axenically in TYI-
S-33 medium supplemented with bile (Sigma) and 10% fetal
bovine serum (13). The organisms were grown in borosilicate
glass tubes (12 by 100 mm) at 37°C, inclined approximately
300 from the horizontal. Trophozoites were subcultured
every 60 to 96 h by chilling the tubes in an ice-water bath for
5 min and then vigorously inverting the tubes to dislodge the
trophozoites. The number of trophozoites per milliliter was
determined, and 5.0 x 104 trophozoites were inoculated into
fresh medium.
Large-scale cultures were cultivated in outside in roller
bottles (Bellco Glass, Inc., Vineland, N.J.), which provide a
high surface area-to-volume ratio (10). Logarithmically
growing trophozoites (2 x 106) were inoculated into each
bottle containing approximately 625 ml of medium. The
roller bottles were incubated at 37°C and rotated at 6
revolutions per h for 70 to 80 h, until an examination of the
surfaces of the bottles by inverse microscopy revealed a
dense monolayer of trophozoites. The bottles were chilled in
an ice water bath for 15 min, and the contents were placed in
250-ml polypropylene bottles and centrifuged in a Sorvall
GSA rotor at 6,000 rpm for 20 min. The pellets were
resuspended in twice their volume of buffer A (50 mM
Tris-HCl [pH 7.5; analytical grade], 100 mM KCl [analytical
grade], 10% glycerol [analytical grade], 10 mM ,-mercap-
toethanol [Sigma], 1 mM phenylmethylsulfonyl fluoride
[PMSF; Sigma], 0.5 mM dithiothreitol [Sigma], 0.5 mM
Na4EDTA [Sigma], 2 mg of aprotinin per ml [Sigma]). The
cell suspension was dropped into liquid nitrogen and stored
at -70°C.
Susceptibility to bis-benzimidazoles. A microculture system
for assessing the antigiardial activity of chemotherapeutic
agents has been previously reported (2, 3). The addition of
Trypticase peptone in the media caused some of the bis-
benzimidazole compounds to fall out of solution, a problem
previously observed in the analysis of pentamidine analogs
(2). Therefore, Trypticase peptone was omitted from the
assay medium for all bis-benzimidazoles and control com-
pounds. This alteration did not greatly interfere with the
growth of the trophozoites during the assay period. G.
lamblia trophozoites were grown to early log phase in
filter-sterilized TYI-S-33 medium supplemented with bile
and 10% fetal bovine serum. Serial dilutions of drugs sus-
pended in assay medium were prepared in duplicate rows of
a 96-well microtiter plate. Spent medium was aspirated from
the culture tubes and replaced with assay medium before the
tubes were chilled, and 2.5 x 104 logarithmically growing
trophozoites were added to wells containing the test agents.
The plates were placed in an anaerobic chamber, gassed with
nitrogen, and incubated at 37°C. After 24 h, [methyl-3H]thy-
midine (1 to 10 Ci/mmol; ICN, Irvine, Calif.) was added to
yield 1.5 to 2 ,uCi per well. At 42 h, the cells were harvested
with a PHD cell harvester (Cambridge Technology, Inc.,
Watertown, Mass.) onto glass microfiber paper. Washed and
dried filters were counted in a Packard Tri-Carb 46-40
scintillation counter.
DNA-binding assay. The binding of this series of bis-
benzimidazoles to calf thymus DNA, poly(dA) poly(dT),
poly(dA-dT) poly(dA-dT), and poly(dG-dC) poly(dG-dC)
was evaluated by a thermal denaturation assay and has been
previously reported (9).
Topoisomerase assays. The activity of topoisomerase II





FIG. 1. ATP dependence of the giardial topoisomerase II on
plasmid relaxation and kinetoplastDNA decatenation. The assay
was performed as described in Materials and Methods. Lanes: 1 to
5, 0.75 pLg of plasmid DNA; 6 to 10 0.5 pg of kDNA. Lanes 1 and 6
are controls (no enzyme); lanes 2, 4, 7, and 9 contain 1 ,ul of a 1/10
dilution of enzyme; and lanes 3, 5, 8, and 10 contain 1 ,ul of
topoisomerase from fraction IV directly.
was monitored throughout the purification steps by utilizing
a relaxation assay. The relaxation of supercoiled plasmid
DNA upon enzyme treatment is among the methods most
commonly used for assessing topoisomerase activity. This
assay takes advantage of the decreased mobility of DNA in
an agarose gel following enzymatic treatment. For the relax-
ation assay, 0.5 ,ug of supercoiled plasmid DNA (pBluescript
II KS+; Stratagene, La Jolla, Calif.) under the conditions of
the assay obtained according to standard methods (16) was
used in a 15-,u reaction mixture containing Topoisomerase II
Reaction Buffer (10 mM Tris-HCl [pH 7.9], 50 mM KCl, 5
mM MgCl2, 0.1 mM EDTA, 15 ,ug of bovine serum albumin
per ml, 1 mM ATP; U.S. Biochemicals, Cleveland, Ohio). A
reaction mixture lacking ATP was also prepared to differen-
tiate between ATP-dependent (topoisomerase II) and ATP-
independent (topoisomerase I) relaxing activities. The reac-
tion mixtures were incubated at 37°C for 15 min and stopped
by the addition of S ,ul of stop buffer containing 5% sodium
dodecyl sulfate, 25% glycerol, and 0.5 mg of bromophenol
blue per ml. The samples were applied to 0.8% horizontal
agarose gels and electrophoresed in Tris-borate-EDTA
buffer for 4 h at 4 V/cm. The gels were stained with ethidium
bromide and photographed under UV light. The extent of
relaxation was determined based on the migration of the
DNA in the gels. Negative photographs of the gels were
scanned with an LKB laser densitometer, and the peak areas
were evaluated. One unit of topoisomerase II was defined as
the amount of enzyme that relaxes 50% of the supercoiled
plasmid DNA in an ATP-dependent manner. Figure 1 illus-
trates the ATP dependence of the reaction.
Preparation of cell extract. The trophozoite suspension
containing approximately 5.8 x 109 organisms (1.6 g [wet
weight]) was thawed at room temperature and lysed by the
addition of an equal amount of buffer A containing 2 M KCl.
The mixture was maintained on ice for 30 min, with periodic
mixing, and then centrifuged in a Sorvall SS34 rotor at
12,000 rpm for 20 min to remove cell debris. The supernatant
was dialyzed against 1 liter of buffer A for 2 h to reduce the
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KCl concentration, and the precipitate was removed by
centrifugation.
Enzyme purification. All purification steps were performed
at 4°C. Chromatographic separation was performed with a
Pharmacia LKB fast-performance liquid chromatography
system consisting of an LKB Controller LCC-500 Plus, two
LKB P-500 pumps, an LKB FRAC-100 fraction collector, an
LKB UV-M Monitor, and an LKB 2210 Chart Recorder
(Pharmacia LKB, Piscataway, N.J.). Protein concentrations
were measured according to the method described by Brad-
ford (4).
CDR. Cell Debris Remover (CDR) (Whatman Biosystems,
Inc., Clifton, N.J.) is a modified cellulose product specifi-
cally designed for the clarification of crude lysates. CDR
absorbs polar lipids, nucleic acids, fats, and cell debris. The
centrifuged dialysate (fraction I) was applied to a CDR
column (1.5 by 5 cm) equilibrated with buffer A and was
washed with 25 ml of buffer A. Protein-containing fractions
were combined for subsequent chromatography (fraction II).
Q-Sepharose fast flow (Pharmacia). Fraction II obtained
from the CDR column was applied to a Q-Sepharose column
(1.5 by 10 cm) equilibrated with buffer A. The column was
washed with 40 ml of buffer A, and the proteins were eluted
with a 50-ml linear gradient of 100 mM to 2 M KCl in buffer
A. The fractions were examined for their abilities to cause
relaxation of supercoiled DNA (form I) to the fully relaxed
state (form II) in the presence (topoisomerase II) and ab-
sence (topoisomerase I) of ATP. Fractions eluting from the
Q-Sepharose column between 450 and 750 mM KCI contain-
ing ATP-dependent relaxation activity were dialyzed against
1 liter of buffer B (100 mM potassium phosphate [pH 7.0],
10% glycerol, 10mM ,-mercaptoethanol, 1 mM PMSF). The
dialysate (fraction III) was clarified by centrifugation for
subsequent chromatography.
Hydroxylapatite. Fraction III obtained from the Q-Sepha-
rose chromatography was applied to a Bio-Gel HTP hydrox-
ylapatite column (1.5 by 5 cm; Bio-Rad Laboratories, Rich-
mond, Calif.). The column was washed with 40 ml of buffer
B, and the protein was eluted with a 40-ml linear gradient of
potassium phosphate (100 mM to 1 M) in buffer B. The
fractions were examined for ATP-dependent relaxation ac-
tivity. The ATP-dependent relaxation activity eluted from
the hydroxylapatite column between 550 and 700 mM potas-
sium phosphate. The active fractions were pooled (fraction
IV) and dialyzed for 2 h against 500 ml of buffer C (50 mM
Tris-HCl [pH 7.5], 100 mM KCl, 20% glycerol, 10 mM
,B-mercaptoethanol, 5 mM dithiothreitol, 0.1 mM Na4-
EDTA]. Fraction IV was dialyzed for an additional 2 h
against buffer C containing 50% glycerol. The dialysate was
aliquoted into 0.65-ml microcentrifuge tubes and stored at
-70°C (stable for over 6 months at -70°C).
Inhibition of topoisomerase II relaxation activity by bis-
benzimidazoles. The possible inhibitory effects of bis-benz-
imidazoles upon ATP-dependent relaxation were deter-
mined. Serial dilutions of the test compounds were made in
96-well microtiter plates. Various concentrations of the
compounds were added to the reaction mixture in 0.65-ml
microcentrifuge tubes. Two units of the enzyme was then
added to each tube, and the reaction mixtures were incu-
bated and electrophoresed as described above. The amounts
of drug (micromolar) required to inhibit 50% of the super-
coiled DNA relaxation were determined.
Data analysis. IC50s for in vitro antigiardial activity and for
DNA binding affinity were determined as previously de-
scribed (2). The IC50s for the inhibition of the relaxing
activity of giardial topoisomerase II were determined by
TABLE 1. Purification of type II topoisomerase from G. lambliaa
Total Sp act Activity
Fraction content (mg) activity (U/mg of recoveredconten(mg) (U)b protein) (%
I (crude lysate) 67.4 1.4 x 105 2.1 x 103 100
II (CDR) 48.3 8.5 x 104 1.8 x 103 60.7
III (Q-Sepharose) 1.9 4.5 x 104 2.3 x 104 32.1
IV (hydroxyapitite) 0.08 9.0 x 103 1.2 x 105 6.4
a The enzyme purification was performed with approximately 5.8 x 109 G.
lamblia trophozoites (1.6 g [wet weight]).
b One unit relaxes half of the supercoiled DNA under the assay conditions.
using scanning densitometry to compare peak areas on
photographic negatives of reactions with and without dica-
tionic agents. The points obtained by scanning densitometry
were graphed, and the IC50s were determined. Statistical
analyses were performed by using the StatView 512+ soft-
ware package (Brainpower, Inc., Calabasas, Calif.) on a
Macintosh LC II microcomputer.
RESULTS
Enzyme purification. Results from a representative purifi-
cation of G. lamblia topoisomerase II are shown in Table 1.
The enzyme purification was performed with a crude cell
extract of approximately 5.8 x 109 trophozoites (1.6 g [wet
weight]). This crude extract had a total protein concentration
of 67.4 mg and a total enzyme activity of about 1.4 x 105 U.
The crude lysate was passed over a CDR column. The CDR
column removed approximately 28% of the total protein and
resulted in a loss of approximately 39% of the starting
ATP-dependent relaxing activity. Protein-containing frac-
tions from the CDR column were applied to a Q-Sepharose
column. ATP-dependent relaxation activity was eluted from
this column between 450 and 750 mM KCI. Passage over the
Q-Sepharose column resulted in a 97% reduction of the total
protein content relative to that of the crude lysate. The
specific activity of the pooled fractions from the Q-Sepha-
rose column represents nearly a 10-fold increase over that of
the crude lysate. The pooled active fractions from the
Q-Sepharose column were applied to a hydroxylapatite
column. Enzymatic activity eluted from the hydroxylapatite
column between 550 and 750 mM of potassium phosphate.
The hydroxylapatite further reduced the total protein con-
tent to less than 0.5% of the starting protein concentration
and raised the specific activity to approximately 1.2 x 105
U/mg of protein. The total topoisomerase II activity recov-
ered after all of the chromatographic steps was approxi-
mately 6.4%. There was no ATP-independent relaxing activ-
ity or apparent nuclease in the final fraction. Figure 1 shows
that the relaxation reaction is ATP dependent after the
addition of either 3 or 30 U of topoisomerase.
Drug susceptibility. Nine bis-benzimidazoles were tested
for in vitro activities against G. lamblia and for their abilities
to inhibit the relaxation of supercoiled DNA by giardial
topoisomerase II. These data, along with the affinities of the
compounds for calf thymus DNA, poly(dA) poly(dT),
poly(dA-dT) poly(dA-dT), and poly(dG-dC) poly(dG-dC)
(9), are presented in Table 2. The compounds are structur-
ally similar, differing only in the presence of either amidino
or imidazolino moieties upon the aromatic rings, in the
number of methylene groups (one to four carbon atoms) in
the linking group joining the benzimidazole groups, or in the
presence of a double bond in the alkyl chain.
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IC50 (p.M) for G. lamblia DNA binding (/Tm ['C] + SD)b
Compound X Ra
no. In vitro activity Topoisomerase Calf thymus Poly(dA). Poly(dA-dT) Poly(dG-dC)
II DNA poly(dT) poly(dA-dT) poly(dG-dC)
1 HC-CH Am 0.04 + 0.01 0.1 21.8 + 0.0 46.1 ± 1.3 42.4 + 0.6 5.8 ± 0.2
2 (CH2)2 Im 0.21 ± 0.03 0.7 18.5 t 0.2 40.0 t 0.9 34.6 ± 1.7 3.0 ± 0.5
3 (CH2)4 Am 8.15 ± 6.9 2 15.9 t 0.5 33.5 t 0.2 31.3 ± 0.4 3.3 ± 0.5
4 (CH2)2 Am 0.33 ± 0.15 4 18.5 t 1.5 42.4 ± 0.7 37.2 ± 1.3 4.0 ± 0.5
5 (CH2)4 Im 14.5 ± 3.5 6 15.3 ± 0.2 34.5 t 0.3 28.9 ± 0.0 4.6 ± 0.1
6 (CH2)3 Im 49.5 ± 7.8 10 9.9 ± 0.2 24.8 t 2.5 20.1 ± 0.3 3.4 ± 0.9
7 (CH2)3 Am 32.5 t 6.4 60 10.6 ± 0.5 30.6 ± 0.1 20.1 ± 0.1 3.3 ± 0.3
8 CH2 Am 307 ± 28.3 520 7.6 t 1.3 9.2 t 0.5 11.5 ± 0.3 3.5 ± 0.2







a Am, amidino; Im, imidazolino.
b Tm, melting temperature. Data are from reference 9.
While each compound demonstrated in vitro activity
against G. lamblia, the antigiardial activities of these com-
pounds varied widely. The IC50s ranged from 0.04 ± 0.01 for
the most-potent molecule to more than 300 ,M. The parent
molecule bis(5-amidino-2-benzimidazolyl)methane (BABIM;
compound 8), a very potent inhibitor of trypsin-like pro-
teases and a promising antiarthritic agent (11, 19), demon-
strated very poor in vitro activity against G. lamblia, with an
IC50 of 307 ± 28.3 ,uM. Compound 9, differing from BABIM
only in the substitution of imidazolino moieties for the
amidino groups, also demonstrated poor in vitro antigiardial
activity. The addition of a second methylene in the link
between the benzimidazole groups (compounds 2 and 4)
resulted in greatly increased in vitro activity against G.
lamblia. The IC50s for the amidino-substituted (compound 4)
and the imidazolino-substituted (compound 2) methylene
derivatives were 0.33 ± 0.15 and 0.21 ± 0.03 ,uM, respec-
tively. Addition of a third methylene (compounds 6 and 7) to
the alkyl bridge resulted in decreased activity relative to
those of the compounds with two methylenes (compounds 2
and 4) but resulted in activity better than those of the
compounds with one methylene joining the benzimidazole
groups (compounds 8 and 9). Compounds with four methyl-
enes (compounds 3 and 5) were more-potent antigiardial
inhibitors than compounds with either one (compounds 8
and 9) or three (compounds 6 and 7) methylenes, but they
demonstrated less in vitro antigiardial activity than the
compounds with two methylenes (compounds 2 and 4). A
bis-benzimidazole in which the benzimidazole groups are
joined by an ethylene group (compound 1) was the most-
potent antigiardial compound tested in this study. The anti-
giardial activity of trans-1,2-bis(5-amidino-2-benzimida-
zolyl)ethene (BBE) (IC50 = 0.04 ± 0.01 ,uM) compares
favorably with those of two compounds currently used to
treat this infection, metronidazole (IC50 = 1.1 + 0.56 ,uM)
and quinacrine-HCl (IC50 = 0.05 + 0.01 ,uM).
DNA binding affinity and its correlation with antigiardial
activity. Each of the nine bis-benzimidazoles exhibited an
affinity for calf thymus DNA, poly(dA) poly(dT), poly(dA-
dT) poly(dA-dT), and poly(dG-dC) poly(dG-dC) in a ther-
mal denaturation assay (9). These compounds showed a
higher affinity for poly(dA) poly(dT) and poly(dA-dT)
poly(dA-dT) than for calf thymus DNA or for poly(dG-dC)
poly(dG-dC). BBE (compound 1), the compound which
demonstrated the strongest antigiardial activity, also showed
the greatest affinity for DNA. Compounds 2 and 4, which
demonstrated pronounced in vitro antigiardial activities, also
bound to calf thymus DNA, poly(dA) poly(dT), and
poly(dA-dT) - poly(dA-dT) with high affinity. Likewise,
compounds 3 and 5 with four methylenes in the alkyl bridge
demonstrated both potent in vitro antigiardial activity and
affinity for calf thymus DNA and the poly(dA). poly(dT)
and poly(dA-dT) - poly(dA-dT) homopolymers. The mole-
cules with one (compounds 8 and 9) and three (compounds 6
and 7) methylenes joining the benzimidazole moieties
showed lower affinity for calf thymus DNA, poly(dA).
poly(dT), and poly(dA-dT) poly(dA-dT) relative to the
other compounds.
The mean IC50s for in vitro activity and for DNA binding
affinity were used to determine the correlations between the
antigiardial activities of these molecules and their affinities
for DNA. The structure-activity relationships may be repre-
sented by the following equations:
-log IC50 IV = 0.26 (+0.02) CT - 0.29 (+0.1) n - 3.67
n = 9 r2 = 0.96 F= 72.9 s = 0.31 (1)
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-log IC50 IV = 0.11 (+0.01) AT - 0.49 (+0.09) n - 3.11
n = 9 2 = 0.97 F = 91.1 s = 0.28 (2)
-log IC50 IV = 0.12 (+0.01) AltAT - 0.37 (±0.09) n - 3.17
n = 9 r2 = 0.97 F= 98.0 s = 0.27 (3)
-log IC50 IV = 0.68 (+0.57) GC - 0.08 (±0.44) n - 3.65 (NS)
n =9 r2=0.19 F=0.73 - s=1.39 (4)
where n is the sample number; r2 is the variance; F is the F
test; s is the standard error of the estimate; -log IC50 IV is
the -log of the in vitro IC50 (micromolar); CT, AT, Alt AT,
and Alt GC, respectively, are calf thymus DNA, poly(dA)
poly(dT), poly(dA-dT). poly(dA-dT), and poly(dG-dC)
poly(dG-dC); NS is not significant; and n is the length of the
alkyl bridge connecting the benzimidazole moieties. These
variables allowed the calculation of the r2 values for the
correlation of antigiardial activity with DNA binding affinity.
There was a very strong correlation between in vitro anti-
giardial activity and the affinities of the compounds for calf
thymus DNA (r2 = 0.96), poly(dA) poly(dT) (r2 = 0.97),
and poly(dA-dT). poly(dA-dT) (r2 = 0.97). There was no
significant correlation between antigiardial activity and the
affinity of molecules for poly(dG-dC). poly(dG-dC) (r2
0.26).
Topoisomerase II inhibition by bis-benzimidazoles and its
correlation with in vitro antigiardial activity and DNA binding
affinity. Each compound inhibited the relaxation of super-
coiled DNA to some degree. These compounds showed a
wide range of topoisomerase II inhibitory concentrations,
with IC50s ranging from 0.1 to more than 600 ,uM. BBE
(compound 1), which demonstrated the most potency against
G. lamblia in vitro and which showed the strongest affinity
for DNA, was also the best inhibitor of the relaxation assay
for topoisomerase II activity. The compounds with a single
methylene connecting the benzimidazole moieties (com-
pounds 8 and 9) were the least-active antigiardial com-
pounds, showed relatively poor affinity for DNA, and also
showed the least inhibitory activity in the topoisomerase II
relaxation assay. Compounds 2 and 4 with two methylenes
showed excellent antigiardial activity and strong affinity for
DNA and were also good inhibitors of the relaxation of
supercoiled DNA by giardial topoisomerase II. Compounds
3 and 5 with four methylenes connecting the benzimidazole
moieties showed more-moderate antigiardial activity, inter-
mediate levels of affinity for DNA, and moderate to good
ability to inhibit the activity of topoisomerase II.
The -log IC50s for the inhibition of giardial topoisomerase
II and in vitro activity and the values for DNA binding
affinity were used to determine the correlations among
topoisomerase II inhibition and the antigiardial activities and
DNA binding affinities of the molecules. There was a strong
correlation between the ability of the compounds to inhibit
the relaxation activity of giardial topoisomerase II and their
in vitro activity against G. lamblia trophozoites (r2 = 0.91),
as is indicated by the following equation, where the -log of
the concentration of drug required to inhibit 50% of the
giardial topoisomerase II relaxation activity is indicated by
-log IC50 IV = 1.102 (+0.14) - log TopolI IC50 - 0.45
(+0.16) n + 1.37
n = 9 r2 = 0.91 F = 30.98 s = 0.46 (5)
Strong correlations were also displayed between the topo-
isomerase II inhibitory activities of bisbenzimidazoles and
the affinities of the molecules for calf thymus DNA (r2 =
0.88), poly(dA) poly(dT) (r2 = 0.84), and poly(dA-dT).
poly(dA-dT) (rZ = 0.90). However, there was no significant
correlation between topoisomerase II inhibition by these
compounds and their affinities for poly(dG-dC) poly(dG-
dC) (r2 = 0.14). These relationships are illustrated by the
following equations:
-log IC50 TII = 0.22 (+0.03) CT - 4.09 (6)
n = 9 r2=0.88 F= 53.36
s = 0.46 P = 0.0002
-log IC50 TII = 0.09 (+0.02) AT - 3.78 (7)
n = 9 r2=0.84 F= 35.92
s = 0.55 P = 0.0005
-log IC50 TII = 0.11 (+0.01) AltAT - 3.78 (8)
n = 9 r2 =0.90 F = 64.60
s = 0.42 P = 0.0001
-log IC50 TII = 0.55 (+0.51) GC - 3.11 (NS)





The prevalence of giardial infections in the United States
and in other parts of the world, coupled with the treatment
failures and side effects associated with current antigiardial
therapies, has led to increased interest in the development of
new antigiardial agents. Benzimidazoles have been shown to
be effective in the treatment of this infection (1). This fact,
along with the demonstrated antigiardial activity of dica-
tionic pentamidine-like molecules, led to the in vitro testing
of a number of dicationically substituted bis-benzimidazoles
against G. lamblia. The data described in the present study
demonstrate that G. lamblia trophozoites are susceptible to
these molecules. Three compounds (compounds 1, 2, and 4)
demonstrated antigiardial activities comparable to those of
drugs currently used to treat giardiasis. The bis-benzimida-
zoles exhibited a strong affinity for calf thymus DNA and the
homopolymers poly(dA). poly(dT) and poly(dA-dT) poly
(dA-dT), and they were also capable of inhibiting the activity
of giardial topoisomerase II. Antigiardial activity correlated
to the affinity of the compounds for calf thymus DNA,
poly(dA) - poly(dT), and poly(dA-dT) poly(dA-dT). The
ability of the bis-benzimidazoles to interfere with the relax-
ation activity of giardial topoisomerase II correlated with
both their in vitro activities against G. lamblia and the
affinity of the molecules for calf thymus DNA, poly(dA)
poly(dT), and poly(dA-dT) - poly(dA-dT).
The DNA binding affinity of dicationically substituted
molecules was previously shown to be related to alkyl chain
length (2, 5). The present study revealed that compounds
containing linkers with an even number of carbon atoms and
a higher affinity for calf thymus DNA, poly(dA) poly(dT)
and poly(dA-dT) poly(dA-dT) demonstrated better in vitro
antigiardial activity than compounds with an odd number of
carbon atoms in the alkyl chains. These compounds, like the
pentamidine derivatives, bind to A+T-rich regions in the
minor groove of DNA without intercalating between base
pairs (9). The preferential binding of these molecules to
A+T-rich regions may explain the strong correlations ob-
served between the antigiardial activities of the compounds
and their affinities for calf thymus DNA, poly(dA). poly
(dT), and poly(dA-dT) poly(dA-dT) and the lack of corre-
lation between antigiardial activity and the affinity of the
molecules for poly(dG-dC) poly(dG-dC). The conformation
of the molecules also appears to be important for their in
vitro activities and DNA binding affinities. Fairley et al.
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reported an association between the radii of curvature of
these molecules and their affinities for DNA (9). Molecules
with radius of curvatures most similar to that of the minor
groove of DNA, i.e., compounds 1, 2, and 4, were more-
potent inhibitors of the in vitro growth of G. lamblia, had a
stronger affinity for DNA, and were also better inhibitors of
giardial topoisomerase II activity.
In conclusion, a new class of agents with promising
antigiardial activity has been identified. This study has also
permitted an evaluation of potential mechanisms of action of
dicationically substituted bis-benzimidazoles. A possible
mechanism(s) of action of these molecules is suggested by
the correlations among their in vitro antigiardial activities,
DNA binding abilities, and topoisomerase II inhibitory ac-
tivities. The strong correlation observed between the DNA
binding affinities of these compounds and their inhibition of
giardial topoisomerase II activity suggests a link between the
topoisomerase II inhibitory activities of bis-benzimidazoles
and their affinities for DNA. The abilities of these molecules
to bind to DNA and to inhibit topoisomerase II should be
exploited to aid in the design of more-potent antigiardial
molecules.
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